CN114848748A - Composition with blood sugar reducing effect and preparation method thereof - Google Patents
Composition with blood sugar reducing effect and preparation method thereof Download PDFInfo
- Publication number
- CN114848748A CN114848748A CN202210642495.2A CN202210642495A CN114848748A CN 114848748 A CN114848748 A CN 114848748A CN 202210642495 A CN202210642495 A CN 202210642495A CN 114848748 A CN114848748 A CN 114848748A
- Authority
- CN
- China
- Prior art keywords
- parts
- tea
- composition
- fenugreek
- mannitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008280 blood Substances 0.000 title claims abstract description 71
- 210000004369 blood Anatomy 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 230000001603 reducing effect Effects 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title abstract description 19
- 235000019224 Camellia sinensis var Qingmao Nutrition 0.000 claims abstract description 53
- 235000020339 pu-erh tea Nutrition 0.000 claims abstract description 53
- 244000250129 Trigonella foenum graecum Species 0.000 claims abstract description 48
- 235000001484 Trigonella foenum graecum Nutrition 0.000 claims abstract description 48
- 235000001019 trigonella foenum-graecum Nutrition 0.000 claims abstract description 48
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 47
- 229930195725 Mannitol Natural products 0.000 claims abstract description 47
- 239000000594 mannitol Substances 0.000 claims abstract description 47
- 235000010355 mannitol Nutrition 0.000 claims abstract description 47
- 241000233779 Cyclocarya paliurus Species 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 32
- 240000000249 Morus alba Species 0.000 claims abstract description 29
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 29
- 235000006533 astragalus Nutrition 0.000 claims abstract description 29
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 21
- 230000002218 hypoglycaemic effect Effects 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 239000000284 extract Substances 0.000 claims description 83
- 241001122767 Theaceae Species 0.000 claims description 61
- 235000013616 tea Nutrition 0.000 claims description 61
- 239000000843 powder Substances 0.000 claims description 52
- 230000002829 reductive effect Effects 0.000 claims description 36
- 238000004806 packaging method and process Methods 0.000 claims description 33
- 238000002156 mixing Methods 0.000 claims description 32
- 230000000694 effects Effects 0.000 claims description 29
- 238000007873 sieving Methods 0.000 claims description 28
- 239000008187 granular material Substances 0.000 claims description 24
- 238000001914 filtration Methods 0.000 claims description 22
- 238000005303 weighing Methods 0.000 claims description 22
- 238000010298 pulverizing process Methods 0.000 claims description 19
- 238000001035 drying Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 15
- 239000009636 Huang Qi Substances 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 13
- 238000005119 centrifugation Methods 0.000 claims description 11
- 239000002131 composite material Substances 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 11
- 239000004744 fabric Substances 0.000 claims description 11
- 238000010992 reflux Methods 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 11
- 230000005855 radiation Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 23
- 230000008901 benefit Effects 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 47
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 20
- 239000008103 glucose Substances 0.000 description 20
- 230000006870 function Effects 0.000 description 15
- 206010012601 diabetes mellitus Diseases 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 238000007908 dry granulation Methods 0.000 description 9
- 239000012467 final product Substances 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 238000001291 vacuum drying Methods 0.000 description 9
- 241001061264 Astragalus Species 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000001678 irradiating effect Effects 0.000 description 8
- 235000012054 meals Nutrition 0.000 description 8
- 210000004233 talus Anatomy 0.000 description 8
- 239000000047 product Substances 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000000291 postprandial effect Effects 0.000 description 4
- 235000021195 test diet Nutrition 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 229930195210 Ophiopogon Natural products 0.000 description 2
- 244000046146 Pueraria lobata Species 0.000 description 2
- 235000010575 Pueraria lobata Nutrition 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000017574 dry cough Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000011990 functional testing Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- OSCCDBFHNMXNME-WDCZJNDASA-N (2s,3s,4r)-2-amino-4-hydroxy-3-methylpentanoic acid Chemical compound C[C@@H](O)[C@@H](C)[C@H](N)C(O)=O OSCCDBFHNMXNME-WDCZJNDASA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 241000758791 Juglandaceae Species 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001448424 Ophiopogon Species 0.000 description 1
- 244000248557 Ophiopogon japonicus Species 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000013400 design of experiment Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000225 effect on diabetes Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- OSCCDBFHNMXNME-UHFFFAOYSA-N gamma-hydroxyisoleucine Natural products CC(O)C(C)C(N)C(O)=O OSCCDBFHNMXNME-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 239000003316 glycosidase inhibitor Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Abstract
The invention relates to a composition with the function of reducing blood sugar and a preparation method thereof, wherein the composition comprises the following components in parts by weight: 3-7 parts of fenugreek, 1-7 parts of cyclocarya paliurus, 1-6 parts of mulberry leaves, 2-8 parts of astragalus membranaceus, 2-8 parts of radix ophiopogonis, 1-6 parts of Pu' er tea and 1-6 parts of mannitol. The invention gives full play to the resource advantages of traditional Chinese medicine, selects fenugreek, cyclocarya paliurus leaves, mulberry leaves, astragalus membranaceus, radix ophiopogonis and Pu' er tea as raw materials under the guidance of the theory of traditional Chinese medicine, and prepares the hypoglycemic product combining modern and traditional methods through reasonable preparation and modern technology.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a composition with a blood sugar reducing effect and a preparation method thereof.
Background
Diabetes has now become one of the most common epidemic diseases worldwide, with its incidence increasing year by year in both developed and developing countries. Statistically, there are 1.6 million type II diabetics worldwide, and by 2025, it is predicted that there will be 3 million people worldwide.
Diabetes is a common endocrine-metabolic disease with a certain genetic tendency, and has the characteristics of many complications, long treatment time and the like. At present, the conventional diabetes treatment is mainly oral hypoglycemic western medicines, mainly sulfonylureas, biguanides, a-glycosidase inhibitors, novel insulin sensitizers and the like, and although the medicines help diabetes patients to control blood sugar level by different action mechanisms, the medicines have side effects such as hypoglycemia, gastrointestinal tract reaction and the like, and simultaneously, the hypoglycemic effect is in a decreasing trend along with the prolonging of treatment time. The traditional Chinese medicine theory considers that diabetes belongs to the category of diabetes, the traditional Chinese medicine for treating diabetes has the characteristics of mild and lasting treatment effect, small side effect, long-term taking and the like, the action mechanism of the traditional Chinese medicine is usually the comprehensive action of multiple targets, multiple effects and multiple functions, and the traditional Chinese medicine has the irreplaceable advantages of western medicines, so that the traditional Chinese medicine is selected by more diabetic patients.
The Chinese patent with application number 201310291634.2 discloses a pure traditional Chinese medicine health food for assisting in reducing blood sugar and a preparation method thereof, and the traditional Chinese medicine compound comprises the following components: 10-15 parts of kudzu root, 6-14 parts of cortex lycii radicis, 6-14 parts of mulberry leaf, 4-10 parts of acanthopanax and 4-10 parts of fenugreek. The kudzu root is used for strengthening the spleen and invigorating yang, and the fenugreek and the like are used as adjuvant drugs, so that the product has the function of assisting in reducing blood sugar from the patent content, but the daily dosage of the product is large, the consumer compliance is poor, and the cost is high.
Therefore, it is highly desirable to provide a composition with long-lasting hypoglycemic effect, low toxic side effect, convenient administration, easy storage and portability, and a preparation method thereof.
Disclosure of Invention
The invention aims to solve the technical problem of providing a composition with the function of reducing blood sugar and a preparation method thereof.
In order to solve the problems, the technical scheme adopted by the invention is as follows:
the composition with the function of reducing blood sugar comprises the following components in parts by weight: 3-7 parts of fenugreek, 1-7 parts of cyclocarya paliurus, 1-6 parts of mulberry leaves, 2-8 parts of astragalus membranaceus, 2-8 parts of radix ophiopogonis, 1-6 parts of Pu' er tea and 1-6 parts of mannitol.
As an embodiment of the invention, the composition is prepared from the following components in parts by weight: 4-6 parts of fenugreek, 2-5 parts of cyclocarya paliurus, 2-5 parts of mulberry leaves, 2-5 parts of astragalus membranaceus, 2-5 parts of radix ophiopogonis, 1-3 parts of Pu' er tea and 1-4 parts of mannitol.
As an embodiment of the invention, the method comprises:
(1) weighing: weighing fenugreek, cyclocarya paliurus, folium mori, radix astragali, radix ophiopogonis, Pu' er tea and mannitol according to the weight parts of the raw materials;
(2) pretreatment: pretreating 1/3 formula amount of Pu 'er tea to obtain Pu' er tea powder; sieving mannitol with 20 mesh sieve;
(3) extraction: adding 12 times of water into the formula amount of the Pu' er tea of fenugreek, cyclocarya paliurus, mulberry leaves, astragalus membranaceus, radix ophiopogonis and 2/3, extracting for 2 times under reflux, extracting for 1 hour each time, filtering the extracting solution, and mixing the filtrates to obtain an extracting solution;
(4) concentrating and drying: performing primary concentration, centrifugation, secondary concentration and drying on the combined filtrate obtained in the step (3) to obtain an extract;
(5) adding the Pu' er tea powder prepared in the step (2), mannitol and the extract prepared in the step (4) into a mixer for mixing;
(6) and granulating the mixed materials by a dry method, and packaging to obtain the composition with the blood sugar reducing effect.
In the step (2), Pu 'er tea with the formula amount of 1/3 is irradiated and then coarsely ground to obtain Pu' er tea coarse powder, the Pu 'er tea coarse powder is screened by a 20-mesh screen, fine powder below 80 meshes is discarded, and Pu' er tea powder with 20-80 meshes is obtained.
As an implementation mode of the invention, 1/3 formula amount of Pu' er tea is irradiated by 60 Co-gamma rays, and the radiation dose is 5 KGy.
As an embodiment of the invention, the step (4) includes:
primary concentration: concentrating the combined filtrate obtained in the step (3) under reduced pressure to 60 ℃, measuring the relative density to be 1.05-1.1, and filtering through 300-mesh filter cloth to obtain a first concentrated extract;
centrifuging: centrifuging the first concentrated extract at 4000rpm/min for 3 min;
and (3) secondary concentration: concentrating the centrifugal supernatant under reduced pressure to 60 ℃, and obtaining a second concentrated extract, wherein the relative density is 1.2-1.25;
and (3) drying: drying the second concentrated extract at 50-65 deg.C under reduced pressure, and pulverizing to obtain extract.
In one embodiment of the invention, the concentration temperature of the primary concentration and the concentration temperature of the secondary concentration are both 40-80 ℃, and the vacuum degree is both 0.04-0.09 MPa.
In step (5), the rotation speed of the mixer is 8 rpm, and the mixing time is 30 min.
In step (6), the mixed materials are dry-granulated and screened by a 20-mesh screen to prepare granules; packaging the granules into tea bags, wherein each bag contains 5g of granules, and packaging with composite film outer bag to obtain the composition with blood sugar lowering effect.
Adopt the produced beneficial effect of above-mentioned technical scheme to lie in:
the invention gives full play to the resource advantages of traditional Chinese medicine, selects fenugreek, cyclocarya paliurus leaves, mulberry leaves, astragalus membranaceus, radix ophiopogonis and Pu' er tea as raw materials under the guidance of the theory of traditional Chinese medicine, and prepares the blood sugar reducing product combining modern and traditional methods through reasonable preparation and modern technology.
In addition, all raw materials in the formula have the effect of directly or indirectly improving diabetes, the fenugreek is used as a monarch drug for warming kidney and tonifying yang, and dispelling cold and relieving pain, the cyclocarya paliurus and the mulberry leaves are used as ministerial drugs for dispelling wind and heat, clearing lung and moistening dryness and enhancing and stabilizing the function of liver yang, and the astragalus and the radix ophiopogonis are used as adjuvant drugs for tonifying qi and invigorating yang, inducing diuresis and relieving swelling, nourishing yin and promoting the production of body fluid. The whole formula has the effects of clearing heat, promoting fluid production, tonifying qi, warming kidney, improving lung dryness and kidney deficiency, mutual compatibility and mutual promotion, synergistic interaction, enhancement of the functions of lung and kidney, and enhancement of the blood sugar regulation capability of an organism, and achieves the effect of reducing blood sugar. In addition, the composition is prepared into a tea preparation by adopting a preparation mode of an extract and tea, so that the drug loading is large, the daily taking frequency is low (2 bags per day), and the problems of high taking frequency of commercially available capsules and tablets and poor consumer compliance are solved.
The results of animal functional evaluation tests and human body feeding tests on the blood sugar reducing tea provided by the invention show that the blood sugar reducing tea has a good blood sugar reducing function.
The description of the raw materials in the composition of the invention is as follows:
fenugreek is dry mature seed of Trigonella foenum-graecum. Bitter and warm herbs enter kidney meridian, and they are famous yang-tonifying herbs. Fenugreek is originally recorded in the principal organ deficiency cold syndrome of Jia you herbal, the bladder qi is treated in Ben Cao Yan Yi, the intestinal qi and hernia of children are treated in He Ji Ju Fang, the cold dampness beriberi, the pain of legs and knees and the weakness of walking are treated in Yang Jia Zang Fang, and the deficiency-cold syndrome of spleen and stomach and the continuous diarrhea are treated in Ben Cao Hui Yan. China is mainly produced in Henan, Hebei, Anhui, Sichuan, Xinjiang and other places, and the places in the south and the north are all cultivated. Research shows that the unique active component 4-hydroxyisoleucine of trigonella foenum graecum seed has the function of promoting glucose uptake of fat cells and skeletal muscle cells, thereby improving insulin resistance. The modern research shows that the fenugreek has a plurality of pharmacological activities, and animal experiments and clinical treatment prove that the fenugreek has good curative effect on diabetes, and can be developed and utilized as a medicament for preventing and treating the diabetes.
Cyclocarya paliurus (cyclocarya paliurus) leaves are leaves of cyclocarya paliurus (a latin name: cyclocarya paliurus) of juglandaceae, are special medicinal plants in China, and have the effects of clearing heat and removing toxicity, promoting the production of body fluid to quench thirst, relieving summer heat, relieving pain and the like according to records of Chinese traditional medicine resource records. Modern researches show that cyclocarya paliurus leaves contain a large amount of flavone, triterpene and polysaccharide, and the alcohol extract and the water extract of the cyclocarya paliurus leaves have obvious effects of reducing blood sugar, blood pressure and blood fat.
The folium Mori is dry leaf of Morus alba L. Sweet, bitter and cold in nature. It enters lung and liver meridians. Has effects of dispelling pathogenic wind and heat, clearing lung-heat, moistening dryness, removing liver fire, and improving eyesight, and can be used for treating wind-heat type common cold, lung heat type dry cough, etc. Folium Mori mainly contains flavonoids, alkaloids, sterols, volatile oil, amino acids, and vitamins. Modern pharmacological studies show that the mulberry leaves have the effects of reducing blood sugar, blood pressure and blood fat, inhibiting fat accumulation and thrombosis, resisting aging, increasing endurance, inhibiting harmful bacteria reproduction and harmful oxide generation in intestinal tracts and the like.
The radix astragali is dried root of Astragalus membranaceus (Fisch.) Bge. of Leguminosae or Astragalus membranaceus (Fisch.) Bge. Sweet and warm. It enters lung and spleen meridians. Has the effects of invigorating qi, invigorating yang, consolidating superficial resistance, arresting sweating, inducing diuresis, relieving swelling, promoting fluid production, and nourishing blood. Modern plant chemistry and pharmacological tests prove that the polysaccharide is one of the main active ingredients of astragalus root and has a plurality of important biological activities. Astragalus polysaccharides have been reported to have significant hypoglycemic effects in diabetic mice.
Radix Ophiopogonis is dried root tuber of Ophiopogon japonica (L.f) Ker-Gawl. of Liliaceae. Sweet, slightly bitter and slightly cold. It enters heart, lung and stomach meridians. Has the effects of nourishing yin, promoting the production of body fluid, moistening lung and clearing away heart-fire. Can be used for treating dry cough due to lung dryness, thirst due to body fluid consumption, internal heat, diabetes, etc. Modern plant chemistry and pharmacological tests prove that the traditional Chinese medicine composition can improve type 2 diabetes from multiple aspects such as blood sugar reduction, glycosylation end product formation inhibition, diabetes complication alleviation and the like.
Drawings
FIG. 1 is a process flow chart of a method for preparing a composition with hypoglycemic effect according to an embodiment of the present invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention will be described in detail and fully with reference to the following embodiments.
Example 1
The composition with the function of reducing blood sugar comprises the following components in parts by weight: 3 parts of fenugreek, 1 part of cyclocarya paliurus, 1 part of mulberry leaf, 2 parts of astragalus membranaceus, 2 parts of radix ophiopogonis, 1 part of Pu' er tea and 1 part of mannitol.
The preparation method comprises the following steps:
(1) weighing: weighing fenugreek, cyclocarya paliurus, folium mori, radix astragali, radix ophiopogonis, Pu' er tea and mannitol according to the weight parts of the raw materials;
(2) pretreatment of
Irradiation and crushing: 1/3 irradiating Pu her tea (60 Co, 5 kGy), and pulverizing to obtain Pu her tea coarse powder.
Sieving: sieving Pu her tea coarse powder with 20 mesh sieve, discarding fine powder below 80 mesh to obtain Pu her tea powder (20-80 mesh); sieving mannitol with 20 mesh sieve.
(3) Extraction of
Adding 12 times of water into the formula amount of the Pu' er tea of fenugreek, cyclocarya paliurus, mulberry leaves, astragalus, radix ophiopogonis and 2/3, extracting for 2 times under reflux, extracting for 1 hour each time, filtering the extracting solution, and mixing the filtrates to obtain the extracting solution for later use.
(4) Concentrating at one time
Concentrating the extract under reduced pressure (concentration temperature 40-80 deg.C, vacuum degree 0.04-0.09 Mpa) to relative density 1.05-1.1 (measured at 60 deg.C), and filtering with 300 mesh filter cloth to obtain concentrated extract I.
(5) Centrifugation
And (4) centrifuging the first concentrated extract for 3min by setting the parameters of a centrifuge at 4000 rpm/min.
(6) Second concentration
And (3) carrying out reduced pressure concentration on the centrifugal supernatant (the concentration temperature is 40-80 ℃, the vacuum degree is 0.04-0.09 Mpa) until the relative density is 1.2-1.25 (measured at 60 ℃), and preparing a second concentrated extract for later use.
(7) Vacuum drying
Drying the concentrated extract at 50-65 deg.C under reduced pressure, and pulverizing to obtain extract.
(8) Mixing
Adding Pu her tea powder (20-80 mesh), mannitol, and extract into mixer, rotating at 8 rpm, and mixing for 30 min.
(9) Dry granulation
The mixed materials are granulated by a dry method and screened by a 20-mesh screen to prepare granules.
(10) Package
Inner packaging: packaging the granules into tea bags, wherein each bag is 5g, and packaging with composite film outer bags to obtain the final product.
Example 2
The composition with the function of reducing blood sugar comprises the following components in parts by weight: 7 parts of fenugreek, 7 parts of cyclocarya paliurus, 6 parts of mulberry leaves, 8 parts of astragalus membranaceus, 8 parts of radix ophiopogonis, 6 parts of Pu' er tea and 6 parts of mannitol.
The preparation method comprises the following steps:
(1) weighing: weighing fenugreek, cyclocarya paliurus, folium mori, radix astragali, radix ophiopogonis, Pu' er tea and mannitol according to the weight parts of the raw materials;
(2) pretreatment of
Irradiation and crushing: 1/3 irradiating Pu her tea (60 Co, 5 kGy), and pulverizing to obtain Pu her tea coarse powder.
Sieving: sieving Pu her tea coarse powder with 20 mesh sieve, discarding fine powder below 80 mesh to obtain Pu her tea powder (20-80 mesh); sieving mannitol with 20 mesh sieve.
(3) Extraction of
Adding 12 times of water into the formula amount of the Pu' er tea of fenugreek, cyclocarya paliurus, mulberry leaves, astragalus, radix ophiopogonis and 2/3, extracting for 2 times under reflux, extracting for 1 hour each time, filtering the extracting solution, and mixing the filtrates to obtain the extracting solution for later use.
(4) Concentrating at one time
Concentrating the extract under reduced pressure (concentration temperature 40-80 deg.C, vacuum degree 0.04-0.09 Mpa) to relative density 1.05-1.1 (measured at 60 deg.C), and filtering with 300 mesh filter cloth to obtain concentrated extract I.
(5) Centrifugation
And (4) centrifuging the first concentrated extract for 3min by setting the parameters of a centrifuge at 4000 rpm/min.
(6) Second concentration
And (3) carrying out reduced pressure concentration on the centrifugal supernatant (the concentration temperature is 40-80 ℃, the vacuum degree is 0.04-0.09 Mpa) until the relative density is 1.2-1.25 (measured at 60 ℃), and preparing a second concentrated extract for later use.
(7) Vacuum drying
Drying the concentrated extract at 50-65 deg.C under reduced pressure, and pulverizing to obtain extract.
(8) Mixing
Adding Pu her tea powder (20-80 mesh), mannitol, and extract into mixer, rotating at 8 rpm, and mixing for 30 min.
(9) Dry granulation
The mixed materials are granulated by a dry method and screened by a 20-mesh screen to prepare granules.
(10) Package (I)
Inner packaging: packaging the granules into tea bags, wherein each bag is 5g, and packaging with composite film outer bags to obtain the final product.
Example 3
The composition with the function of reducing blood sugar comprises the following components in parts by weight: 4 parts of fenugreek, 3 parts of cyclocarya paliurus, 3 parts of mulberry leaves, 4 parts of astragalus membranaceus, 4 parts of radix ophiopogonis, 2 parts of Pu' er tea and 2 parts of mannitol.
The preparation method comprises the following steps:
(1) weighing: weighing fenugreek, cyclocarya paliurus, folium mori, radix astragali, radix ophiopogonis, Pu' er tea and mannitol according to the weight parts of the raw materials;
(2) pretreatment of
Irradiation and crushing: 1/3 irradiating Pu her tea (60 Co, 5 kGy), and pulverizing to obtain Pu her tea coarse powder.
Sieving: sieving Pu her tea coarse powder with 20 mesh sieve, discarding fine powder below 80 mesh to obtain Pu her tea powder (20-80 mesh); sieving mannitol with 20 mesh sieve.
(3) Extraction of
Adding 12 times of water into the formula amount of the Pu' er tea of fenugreek, cyclocarya paliurus, mulberry leaves, astragalus, radix ophiopogonis and 2/3, extracting for 2 times under reflux, extracting for 1 hour each time, filtering the extracting solution, and mixing the filtrates to obtain the extracting solution for later use.
(4) Concentrating at one time
Concentrating the extract under reduced pressure (concentration temperature 40-80 deg.C, vacuum degree 0.04-0.09 Mpa) to relative density 1.05-1.1 (measured at 60 deg.C), and filtering with 300 mesh filter cloth to obtain concentrated extract I.
(5) Centrifugation
And (4) centrifuging the first concentrated extract for 3min by setting the parameters of a centrifuge at 4000 rpm/min.
(6) Second concentration
And (3) carrying out reduced pressure concentration on the centrifugal supernatant (the concentration temperature is 40-80 ℃, the vacuum degree is 0.04-0.09 Mpa) until the relative density is 1.2-1.25 (measured at 60 ℃), and preparing a second concentrated extract for later use.
(7) Vacuum drying
Drying the concentrated extract at 50-65 deg.C under reduced pressure, and pulverizing to obtain extract.
(8) Mixing
Adding Pu her tea powder (20-80 mesh), mannitol, and extract into mixer, rotating at 8 rpm, and mixing for 30 min.
(9) Dry granulation
The mixed materials are granulated by a dry method and screened by a 20-mesh screen to prepare granules.
(10) Package (I)
Inner packaging: packaging the granules into tea bags, wherein each bag is 5g, and packaging with composite film outer bags to obtain the final product.
Example 4
The composition with the function of reducing blood sugar comprises the following components in parts by weight: 3 parts of fenugreek, 4 parts of cyclocarya paliurus, 4 parts of mulberry leaves, 3 parts of astragalus membranaceus, 3 parts of radix ophiopogonis, 2 parts of Pu' er tea and 3 parts of mannitol.
The preparation method comprises the following steps:
(1) weighing: weighing fenugreek, cyclocarya paliurus, folium mori, radix astragali, radix ophiopogonis, Pu' er tea and mannitol according to the weight parts of the raw materials;
(2) pretreatment of
Irradiation and crushing: 1/3 irradiating Pu her tea (60 Co, 5 kGy), and pulverizing to obtain Pu her tea coarse powder.
Sieving: sieving Pu her tea coarse powder with 20 mesh sieve, discarding fine powder below 80 mesh to obtain Pu her tea powder (20-80 mesh); sieving mannitol with 20 mesh sieve.
(3) Extraction of
Adding 12 times of water into the fenugreek, cyclocarya paliurus, mulberry leaves, astragalus membranaceus, radix ophiopogonis and 2/3 Pu' er tea according to the formula amount, extracting for 2 times by reflux, extracting for 1 hour each time, filtering the extracting solution, and mixing the filtrates to obtain the extracting solution for later use.
(4) Concentrating at one time
Concentrating the extract under reduced pressure (concentration temperature 40-80 deg.C, vacuum degree 0.04-0.09 Mpa) to relative density 1.05-1.1 (measured at 60 deg.C), and filtering with 300 mesh filter cloth to obtain concentrated extract I.
(5) Centrifugation
And (4) centrifuging the first concentrated extract for 3min by setting the parameters of a centrifuge at 4000 rpm/min.
(6) Second concentration
And (3) carrying out reduced pressure concentration on the centrifugal supernatant (the concentration temperature is 40-80 ℃, the vacuum degree is 0.04-0.09 Mpa) until the relative density is 1.2-1.25 (measured at 60 ℃), and preparing a second concentrated extract for later use.
(7) Vacuum drying
Drying the concentrated extract at 50-65 deg.C under reduced pressure, and pulverizing to obtain extract.
(8) Mixing
Adding Pu her tea powder (20-80 mesh), mannitol, and extract into mixer, rotating at 8 rpm, and mixing for 30 min.
(9) Dry granulation
The mixed materials are granulated by a dry method and screened by a 20-mesh screen to prepare granules.
(10) Package (I)
Inner packaging: packaging the granules into tea bags, wherein each bag is 5g, and packaging with composite film outer bags to obtain the final product.
Example 5
The composition with the function of reducing blood sugar comprises the following components in parts by weight: 5 parts of fenugreek, 4 parts of cyclocarya paliurus, 4 parts of mulberry leaves, 4 parts of astragalus membranaceus, 4 parts of radix ophiopogonis, 2 parts of Pu' er tea and 3 parts of mannitol.
The preparation method comprises the following steps:
(1) weighing: weighing fenugreek, cyclocarya paliurus, folium mori, radix astragali, radix ophiopogonis, Pu' er tea and mannitol according to the weight parts of the raw materials;
(2) pretreatment of
Irradiation and crushing: 1/3 irradiating Pu her tea (60 Co, 5 kGy), and pulverizing to obtain Pu her tea coarse powder.
Sieving: sieving Pu her tea coarse powder with 20 mesh sieve, discarding fine powder below 80 mesh to obtain Pu her tea powder (20-80 mesh); sieving mannitol with 20 mesh sieve.
(3) Extraction of
Adding 12 times of water into the formula amount of the Pu' er tea of fenugreek, cyclocarya paliurus, mulberry leaves, astragalus, radix ophiopogonis and 2/3, extracting for 2 times under reflux, extracting for 1 hour each time, filtering the extracting solution, and mixing the filtrates to obtain the extracting solution for later use.
(4) Concentrating at one time
Concentrating the extract under reduced pressure (concentration temperature 40-80 deg.C, vacuum degree 0.04-0.09 Mpa) to relative density 1.05-1.1 (measured at 60 deg.C), and filtering with 300 mesh filter cloth to obtain concentrated extract I.
(5) Centrifugation
And (4) centrifuging the first concentrated extract for 3min by setting the parameters of a centrifuge at 4000 rpm/min.
(6) Second concentration
And (3) carrying out reduced pressure concentration on the centrifugal supernatant (the concentration temperature is 40-80 ℃, the vacuum degree is 0.04-0.09 Mpa) until the relative density is 1.2-1.25 (measured at 60 ℃), and preparing a second concentrated extract for later use.
(7) Vacuum drying
Drying the concentrated extract at 50-65 deg.C under reduced pressure, and pulverizing to obtain extract.
(8) Mixing of
Adding Pu her tea powder (20-80 mesh), mannitol, and extract into mixer, rotating at 8 rpm, and mixing for 30 min.
(9) Dry granulation
The mixed materials are granulated by a dry method and screened by a 20-mesh screen to prepare granules.
(10) Package (I)
Inner packaging: packaging the granules into tea bags, wherein each bag is 5g, and packaging with composite film outer bags to obtain the final product.
Comparative example 1:
the composition comprises the following components in parts by weight: 4 parts of fenugreek, 3 parts of cyclocarya paliurus, 3 parts of mulberry leaves, 4 parts of astragalus membranaceus, 4 parts of radix ophiopogonis and 2 parts of mannitol.
The preparation method comprises the following steps:
(1) weighing: weighing fenugreek, cyclocarya paliurus, folium mori, radix astragali, radix ophiopogonis and mannitol according to the weight parts of the raw materials;
(2) pretreatment of
Sieving: sieving mannitol with 20 mesh sieve.
(3) Extraction of
Adding 12 times of water into fenugreek, cyclocarya paliurus, folium mori, radix astragali and radix ophiopogonis, extracting for 2 times under reflux, extracting for 1 hour each time, filtering the extracting solution, and combining the filtrates to obtain the extracting solution for later use.
(4) Concentrating at one time
Concentrating the extract under reduced pressure (concentration temperature 40-80 deg.C, vacuum degree 0.04-0.09 Mpa) to relative density 1.05-1.1 (measured at 60 deg.C), and filtering with 300 mesh filter cloth to obtain concentrated extract I.
(5) Centrifugation
And (4) centrifuging the first concentrated extract for 3min by setting the parameters of a centrifuge at 4000 rpm/min.
(6) Second concentration
And (3) carrying out reduced pressure concentration on the centrifugal supernatant (the concentration temperature is 40-80 ℃, the vacuum degree is 0.04-0.09 Mpa) until the relative density is 1.2-1.25 (measured at 60 ℃), and preparing a second concentrated extract for later use.
(7) Vacuum drying
Drying the concentrated extract at 50-65 deg.C under reduced pressure, and pulverizing to obtain extract.
(8) Mixing
Adding mannitol and extract into mixer, rotating at 8 rpm, and mixing for 30 min.
(9) Dry granulation
The mixed materials are granulated by a dry method and screened by a 20-mesh screen to prepare granules.
(10) Package (I)
Inner packaging: packaging the granules into tea bags, wherein each bag is 5g, and packaging with composite film outer bags to obtain the final product.
Comparative example 2
The composition comprises the following components in parts by weight: 4 parts of fenugreek, 3 parts of cyclocarya paliurus, 3 parts of mulberry leaves, 4 parts of astragalus membranaceus, 2 parts of Pu' er tea and 2 parts of mannitol.
The preparation method comprises the following steps:
(1) weighing: weighing fenugreek, cyclocarya paliurus, folium mori, radix astragali, Pu' er tea and mannitol according to the weight parts of the raw materials;
(2) pretreatment of
Irradiation and crushing: 1/3 irradiating Pu her tea (60 Co, 5 kGy), and pulverizing to obtain Pu her tea coarse powder.
Sieving: sieving Pu her tea coarse powder with 20 mesh sieve, discarding fine powder below 80 mesh to obtain Pu her tea powder (20-80 mesh); sieving mannitol with 20 mesh sieve.
(3) Extraction of
Adding 12 times of water into fenugreek, cyclocarya paliurus, folium mori, radix astragali and 2/3 formula amount of Pu' er tea, extracting under reflux for 2 times, each time for 1 hour, filtering the extract, and mixing the filtrates to obtain the extract for later use.
(4) Concentrating at one time
Concentrating the extract under reduced pressure (concentration temperature 40-80 deg.C, vacuum degree 0.04-0.09 Mpa) to relative density 1.05-1.1 (measured at 60 deg.C), and filtering with 300 mesh filter cloth to obtain concentrated extract I.
(5) Centrifugation
And (4) centrifuging the first concentrated extract for 3min by setting the parameters of a centrifuge at 4000 rpm/min.
(6) Second concentrating
And (3) carrying out reduced pressure concentration on the centrifugal supernatant (the concentration temperature is 40-80 ℃, the vacuum degree is 0.04-0.09 Mpa) until the relative density is 1.2-1.25 (measured at 60 ℃), and preparing a second concentrated extract for later use.
(7) Vacuum drying
Drying the concentrated extract at 50-65 deg.C under reduced pressure, and pulverizing to obtain extract.
(8) Mixing
Adding Pu her tea powder (20-80 mesh), mannitol, and extract into mixer, rotating at 8 rpm, and mixing for 30 min.
(9) Dry granulation
The mixed materials are granulated by a dry method and screened by a 20-mesh screen to prepare granules.
(10) Package (I)
Inner packaging: packaging the granules into tea bags, wherein each bag is 5g, and packaging with composite film outer bags to obtain the final product.
Comparative example 3
The composition comprises the following components in parts by weight: 4 parts of fenugreek, 3 parts of cyclocarya paliurus, 3 parts of mulberry leaves, 4 parts of astragalus membranaceus, 4 parts of radix ophiopogonis, 0.5 part of Pu' er tea and 2 parts of mannitol.
(1) Weighing: weighing fenugreek, cyclocarya paliurus, folium mori, radix astragali, radix ophiopogonis, Pu' er tea and mannitol according to the weight parts of the raw materials;
(2) pretreatment of
Irradiation and crushing: 1/3 irradiating Pu her tea (60 Co, 5 kGy), and pulverizing to obtain Pu her tea coarse powder.
Sieving: sieving Pu her tea coarse powder with 20 mesh sieve, discarding fine powder below 80 mesh to obtain Pu her tea powder (20-80 mesh); sieving mannitol with 20 mesh sieve.
(3) Extraction of
Adding 12 times of water into the formula amount of the Pu' er tea of fenugreek, cyclocarya paliurus, mulberry leaves, astragalus, radix ophiopogonis and 2/3, extracting for 2 times under reflux, extracting for 1 hour each time, filtering the extracting solution, and mixing the filtrates to obtain the extracting solution for later use.
(4) Concentrating at one time
Concentrating the extract under reduced pressure (concentration temperature 40-80 deg.C, vacuum degree 0.04-0.09 Mpa) to relative density 1.05-1.1 (measured at 60 deg.C), and filtering with 300 mesh filter cloth to obtain concentrated extract I.
(5) Centrifugation
And (4) centrifuging the first concentrated extract for 3min by setting the parameters of a centrifuge at 4000 rpm/min.
(6) Second concentration
And (3) carrying out reduced pressure concentration on the centrifugal supernatant (the concentration temperature is 40-80 ℃, the vacuum degree is 0.04-0.09 Mpa) until the relative density is 1.2-1.25 (measured at 60 ℃), and preparing a second concentrated extract for later use.
(7) Vacuum drying
Drying the concentrated extract at 50-65 deg.C under reduced pressure, and pulverizing to obtain extract.
(8) Mixing
Adding Pu her tea powder (20-80 mesh), mannitol, and extract into mixer, rotating at 8 rpm, and mixing for 30 min.
(9) Dry granulation
The mixed materials are granulated by a dry method and screened by a 20-mesh screen to prepare granules.
(10) Package
Inner packaging: packaging the granules into tea bags, wherein each bag is 5g, and packaging with composite film outer bags to obtain the final product.
Comparative example 4
The composition comprises the following components in parts by weight: 2 parts of fenugreek, 3 parts of cyclocarya paliurus, 3 parts of mulberry leaves, 4 parts of astragalus membranaceus, 4 parts of radix ophiopogonis, 7 parts of Pu' er tea and 2.5 parts of mannitol.
(1) Weighing: weighing fenugreek, cyclocarya paliurus, folium mori, radix astragali, radix ophiopogonis, Pu' er tea and mannitol according to the weight parts of the raw materials;
(2) pretreatment of
Irradiation and crushing: 1/3 irradiating Pu her tea (60 Co, 5 kGy), and pulverizing to obtain Pu her tea coarse powder.
Sieving: sieving Pu her tea coarse powder with 20 mesh sieve, discarding fine powder below 80 mesh to obtain Pu her tea powder (20-80 mesh); sieving mannitol with 20 mesh sieve.
(3) Extraction of
Adding 12 times of water into the formula amount of the Pu' er tea of fenugreek, cyclocarya paliurus, mulberry leaves, astragalus, radix ophiopogonis and 2/3, extracting for 2 times under reflux, extracting for 1 hour each time, filtering the extracting solution, and mixing the filtrates to obtain the extracting solution for later use.
(4) Concentrating at one time
Concentrating the extract under reduced pressure (concentration temperature 40-80 deg.C, vacuum degree 0.04-0.09 Mpa) to relative density 1.05-1.1 (measured at 60 deg.C), and filtering with 300 mesh filter cloth to obtain concentrated extract I.
(5) Centrifugation
And (4) centrifuging the first concentrated extract for 3min by setting the parameters of a centrifuge at 4000 rpm/min.
(6) Second concentration
And (3) carrying out reduced pressure concentration on the centrifugal supernatant (the concentration temperature is 40-80 ℃, the vacuum degree is 0.04-0.09 Mpa) until the relative density is 1.2-1.25 (measured at 60 ℃), and preparing a second concentrated extract for later use.
(7) Vacuum drying
Drying the concentrated extract at 50-65 deg.C under reduced pressure, and pulverizing to obtain extract.
(8) Mixing
Adding Pu her tea powder (20-80 mesh), mannitol, and extract into mixer, rotating at 8 rpm, and mixing for 30 min.
(9) Dry granulation
The mixed materials are granulated by a dry method and screened by a 20-mesh screen to prepare granules.
(10) Package
Inner packaging: packaging the granules into tea bags, wherein each bag is 5g, and packaging with composite film outer bags to obtain the final product.
Effect example 1: functional test of animals
(1) Test examples
Animal function tests were carried out on the hypoglycemic compositions prepared in examples 1 to 5 and the hypoglycemic compositions prepared in comparative examples 1 to 4, and the hypoglycemic effect of the present invention was investigated.
(2) Laboratory animal
100 male Kunming rats with the body weight of 160-200 g are selected. And constructing a hyperglycemic model of islet injury by adopting alloxan. The method comprises the following steps: after 3-5 days of acclimation, 10 animals were randomly fasted for 3-5 hours, and fasting blood glucose was measured as the basal blood glucose level of the batch. Then the animals are fasted for 24 hours (free drinking water), the animals are injected with alloxan (prepared by fresh preparation before use) according to 60mg/kg BW.iv of rats for molding, the animals are fasted for 3 to 5 hours after 6 days of administration, the blood sugar is measured, and the blood sugar value is 10 to 25mmol/L, which is the successful animal of a hyperglycemic model.
The model rats were randomly divided into 10 groups for experiment. 10 rats were gazed in each group, 9 rats were gazed with the solution of the composition prepared in the above test example, and 1 mouse was gazed with sterile water as a model control.
(3) Gavage method and dosage
The recommended dosage of the sample is 6g extract per day for an adult (measured as 60kg body weight), corresponding to 0.1 g/day/kg body weight. The experiment is designed to be 5 times of the recommended amount of a human body, namely, the stomach is irrigated with 0.5g/kgBW per day. The method for treating the test object comprises the following steps: sterile water is used for preparing solutions with the concentration of 0.5g/10mL respectively for standby. Orally administered once a day for 4 weeks, measuring fasting blood glucose, and comparing blood glucose of each group of animals. The gavage volume of the rats was 1.0mL/100g of the weight of the rats.
The model control group was (0g/kgBW), and the test subjects were replaced with water (sterilized), and the daily gavage volume was the same as that of each test subject group.
(4) A detection instrument:
a blood glucose meter for measuring blood glucose by Johnson Touch Horizon and a matched test paper.
(5) Data processing
Generally, analysis of variance is adopted, but the program of analysis of variance is firstly used for carrying out homogeneity of variance test, homogeneity of variance and calculationFThe value of the one or more of the one,Fvalue of<F 0.05 And the conclusion is that: the difference between the average numbers of all groups is not significant;Fvalue of not less thanF 0.05 ，PLess than or equal to 0.05, and counting by using a pairwise comparison method of the mean number between a plurality of experimental groups and a control group; carrying out appropriate variable conversion on the data which are not normal or uneven in variance, and counting by using the converted data after the requirements of normal or uniform variance are met; if the variable still does not reach the goal of being normal or uniform in variance after conversion, the statistics is carried out by using the rank sum test.
(6) The test results obtained are shown in table 1.
As can be seen from the experimental results in Table 2, compared with the model control group, the fasting blood glucose value of the rats gavaged with the blood glucose reducing composition provided in examples 1-5 is significantly reduced after the experiment, and the rats show good blood glucose reducing efficacy.
Compared with example 3, comparative examples 1-2 lack pu 'er tea and ophiopogon root components, respectively, and the ratio between pu' er tea in comparative example 3 and fenugreek in comparative example 4 is not within the range defined by the present invention, resulting in that the blood glucose values of rats gavaged with the components in comparative examples 1-4 are consistent with those of model controls, i.e., do not show the blood glucose lowering effect. Therefore, the formula of the invention has the effect of synergistically enhancing the blood sugar reducing effect, and when part of components or the proportion of the components is beyond the range defined by the invention, the synergistic effect is influenced, so that the blood sugar reducing effect is reduced.
Effect example 2: functional test for human body eating test
The testers took the tea soaked in the tea bags obtained in example 3 and comparative example 1, respectively, and conducted a human body eating trial test function test.
(1) Test subject
The disease condition is stable after diet control or oral hypoglycemic drug treatment, and only adult type II diabetic subjects (DM) with maintenance dose, namely fasting blood sugar is more than or equal to 7mmol/L (126 mg/dl) or 2 hours after meal blood sugar is more than or equal to 11.lmmol/L (200mg/dl), are taken without changing the variety and dosage of the drug.
② the Impaired Glucose Regulation (IGR) population with 5.6-7mmol/L of fasting blood glucose (100-126mg/dl) or 7.8-11 lmmol/L of blood glucose (140-200 mg/dl) after 2 hours.
(2) Design of experiments and grouping
Two control designs, self and group, were used. And grouping according to the requirement of a random blind method. The blood sugar level of the subject is randomly divided into a test food group and a control group, and main factors influencing the result, such as the course of disease, the type of medicine taking and the like, are considered as much as possible to carry out balance test so as to ensure comparability among the groups. Each group had 60 subjects. The test group took the tea obtained by soaking the tea bag obtained in example 3, and the control group took the tea obtained by soaking the tea bag obtained in comparative example 1.
(3) Dosage and method of administration
It is administered orally with hot water for 45 days 2 times a day, 1 bag each time.
(4) Observation index
Firstly, symptom observation: inquiring the medical history in detail, knowing the diet, administration and activity of the patients, observing the main clinical symptoms of thirst, polydipsia, polyphagia, listlessness, hypodynamia, polyuria and the like, counting the integral values before and after the test according to the weight of the symptoms, improving the main symptoms (the improvement 1 is effective), and observing the improvement rate of the clinical symptoms.
TABLE 2 clinical symptom score chart
② fasting blood sugar: observing the fasting blood sugar value, the fasting blood sugar reduction percentage and the fasting blood sugar effective rate before and after the test.
③ 2h of blood sugar after meal: observing blood sugar value 2h after eating 100g fine flour dumpling head before and after the test, blood sugar reduction percentage 2h after meal, and blood sugar effective rate 2h after meal.
Fourthly, side effects and taste acceptance are as follows: and observing whether two groups of testees have feedback of side effects in the process of eating trial, and simultaneously investigating the condition of the taste acceptance of the product.
Judging effective standard of efficacy:
the method has the following advantages: a. after the test, the fasting blood glucose is recovered to be normal (less than or equal to 5.6 mmol/L), or the fasting blood glucose is reduced by more than or equal to 10 percent;
b. after the test, the blood sugar returns to normal (less than or equal to 7.8 mmol/L) after 2 hours of meal, or the blood sugar drop amplitude after 2 hours of meal is more than or equal to 10 percent.
And (4) invalidation: the effective standard is not reached.
(5) Data processing and statistical analysis
The self-control data can be tested by paired t tests, and the two-group mean comparison can be tested by grouped t tests, the latter needs to be testedAnd carrying out homogeneity of variance test, carrying out proper variation conversion on the data with non-normal distribution or uneven variance, and carrying out t test on the converted data after the normal variance is met. Effective rate adopts x 2 And (5) checking to carry out checking.
(6) As a result, the
The test diet test is carried into 120 cases of test subjects, 60 cases of test diet groups and control groups respectively, 3 cases of the test diet groups and 5 cases of the control groups are respectively separated after the test is finished, and the effective cases of the test diet groups and the control groups are 57 cases and 55 cases respectively.
Comparing general data before test: the subjects were asked and examined before the test, and the general data of the test group and the control group were compared, and the differences were not statistically significant (1)P>0.05), the two sets of basic data are comparable.
Secondly, the efficacy index influences one: effects on fasting and postprandial 2-hour blood glucose
After the test, the fasting blood sugar and the postprandial blood sugar of the test group after 2 hours and the reduction rate before and after the test are compared with the control group, and the difference has statistical significance (P<0.05); the differences between fasting blood glucose before and after the test and 2 hours blood glucose after meal have statistical significance: (P<0.05), whereas the control group compared to itself, the difference was not statistically significant (P>0.05), the results are shown in table 3.
TABLE 3 fasting plasma glucose and postprandial 2-hour plasma glucose changes before and after the test meal
Third, the effect index influences the second: effective rate comparison of each efficacy index
The effective rates of fasting blood sugar and postprandial 2-hour blood sugar of the test food groups are respectively 43.90 percent and 40.4 percent, and the differences have statistical significance compared with a control group (P<0.05), which shows that the blood sugar reducing effect of the test group is obviously better than that of the control group, and the table 4 shows.
TABLE 4
Effect index influences three: comparison of Total integral Change in clinical symptoms
The total clinical symptom score of the test food group after the test and the reduction rate before and after the test are compared with the control group, and the difference has statistical significance (P<0.05); the total score of clinical symptoms before and after the test group is compared with the total score of clinical symptoms, and the difference has statistical significance (P<0.05); while the control group had no statistical significance in comparison with the difference by itself (P>0.05) as detailed in table 5.
TABLE 5 Total integral of clinical symptoms before and after the test
The efficacy index influences four: side effects and taste acceptability
The incidence rate of side effects in the test group is 7.0%, which is obviously lower than that in the control group, and the difference has statistical significance (1)P<0.05); the acceptance rate of the test group to the product is 89.5 percent, which is obviously higher than that of the control group, and the difference has statistical significance (P<0.05), the results are shown in tables 6 and 7.
TABLE 6 comparison of adverse effects
TABLE 7 comparison of product mouthfeel acceptability
Claims (9)
1. The composition with the effect of reducing blood sugar is characterized by comprising the following components in parts by weight: 3-7 parts of fenugreek, 1-7 parts of cyclocarya paliurus, 1-6 parts of mulberry leaves, 2-8 parts of astragalus membranaceus, 2-8 parts of radix ophiopogonis, 1-6 parts of Pu' er tea and 1-6 parts of mannitol.
2. The composition with the hypoglycemic effect according to claim 1, wherein the composition comprises the following components in parts by weight: 4-6 parts of fenugreek, 2-5 parts of cyclocarya paliurus, 2-5 parts of mulberry leaves, 2-5 parts of astragalus membranaceus, 2-5 parts of radix ophiopogonis, 1-3 parts of Pu' er tea and 1-4 parts of mannitol.
3. A method for preparing a composition having a hypoglycemic effect, said method comprising:
(1) weighing: weighing fenugreek, cyclocarya paliurus, folium mori, radix astragali, radix ophiopogonis, Pu' er tea and mannitol according to the weight parts of the raw materials;
(2) pretreatment: pretreating 1/3 formula amount of Pu 'er tea to obtain Pu' er tea powder; sieving mannitol with 20 mesh sieve;
(3) extraction: adding 12 times of water into the formula amount of the Pu' er tea of fenugreek, cyclocarya paliurus, mulberry leaves, astragalus membranaceus, radix ophiopogonis and 2/3, extracting for 2 times under reflux, extracting for 1 hour each time, filtering the extracting solution, and mixing the filtrates to obtain an extracting solution;
(4) concentrating and drying: performing primary concentration, centrifugation, secondary concentration and drying on the combined filtrate obtained in the step (3) to obtain an extract;
(5) adding the Pu' er tea powder prepared in the step (2), mannitol and the extract prepared in the step (4) into a mixer for mixing;
(6) and granulating the mixed materials by a dry method, and packaging to obtain the composition with the blood sugar reducing effect.
4. The method for preparing a composition with hypoglycemic effect according to claim 3, wherein in the step (2), 1/3 formula amount of Pu 'er tea is irradiated and then coarsely pulverized to obtain Pu' er tea coarse powder, the Pu 'er tea coarse powder is sieved by a 20-mesh sieve, and 80-mesh or less fine powder is discarded to obtain 20-80-mesh Pu' er tea powder.
5. The method for preparing a composition with hypoglycemic effect according to claim 4, wherein 1/3 formula amount of Pu' er tea is irradiated by 60 Co-gamma ray with radiation dose of 5 KGy.
6. The method for preparing a composition with hypoglycemic effect according to claim 3, wherein the step (4) comprises:
primary concentration: concentrating the combined filtrate obtained in the step (3) under reduced pressure to 60 ℃, measuring the relative density to be 1.05-1.1, and filtering through 300-mesh filter cloth to obtain a first concentrated extract;
centrifuging: centrifuging the first concentrated extract at 4000rpm/min for 3 min;
and (3) secondary concentration: concentrating the centrifugal supernatant under reduced pressure to 60 ℃, and obtaining a second concentrated extract, wherein the relative density is 1.2-1.25;
and (3) drying: drying the second concentrated extract at 50-65 deg.C under reduced pressure, and pulverizing to obtain extract.
7. The method for preparing the composition with hypoglycemic effect according to claim 6, wherein the concentration temperature of the first concentration and the concentration temperature of the second concentration are both 40-80 ℃ and the vacuum degree is both 0.04-0.09 MPa.
8. The method for preparing a composition with hypoglycemic effect according to claim 3, wherein in step (5), the rotation speed of the mixer is 8 rpm, and the mixing time is 30 min.
9. The method for preparing a composition with hypoglycemic effect according to claim 3, wherein in step (6), the mixed materials are dry granulated and screened by a 20-mesh screen to obtain granules; packaging the granules into tea bags, wherein each bag contains 5g of granules, and packaging with composite film outer bag to obtain the composition with blood sugar lowering effect.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210642495.2A CN114848748B (en) | 2022-06-08 | 2022-06-08 | Composition with blood sugar reducing effect and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210642495.2A CN114848748B (en) | 2022-06-08 | 2022-06-08 | Composition with blood sugar reducing effect and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114848748A true CN114848748A (en) | 2022-08-05 |
| CN114848748B CN114848748B (en) | 2023-04-28 |
Family
ID=82623717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210642495.2A Active CN114848748B (en) | 2022-06-08 | 2022-06-08 | Composition with blood sugar reducing effect and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114848748B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101336974A (en) * | 2008-08-07 | 2009-01-07 | 华中科技大学同济医学院附属同济医院 | Traditional Chinese medicine for reducing blood sugar and regulating lipid with overall regulation of body metabolism and preparation method thereof |
| CN107319553A (en) * | 2017-07-10 | 2017-11-07 | 溧阳市天目湖保健品有限公司 | A kind of health products of auxiliary hyperglycemic strengthen immunity and preparation method thereof |
| CN107412341A (en) * | 2017-04-17 | 2017-12-01 | 中国药科大学 | A kind of hypoglycemic formula containing blue or green money willow and preparation method thereof |
| CN113826731A (en) * | 2021-09-22 | 2021-12-24 | 贺新义 | Preparation method of green mulberry and citrus Pu' er tea |
-
2022
- 2022-06-08 CN CN202210642495.2A patent/CN114848748B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101336974A (en) * | 2008-08-07 | 2009-01-07 | 华中科技大学同济医学院附属同济医院 | Traditional Chinese medicine for reducing blood sugar and regulating lipid with overall regulation of body metabolism and preparation method thereof |
| CN107412341A (en) * | 2017-04-17 | 2017-12-01 | 中国药科大学 | A kind of hypoglycemic formula containing blue or green money willow and preparation method thereof |
| CN107319553A (en) * | 2017-07-10 | 2017-11-07 | 溧阳市天目湖保健品有限公司 | A kind of health products of auxiliary hyperglycemic strengthen immunity and preparation method thereof |
| CN113826731A (en) * | 2021-09-22 | 2021-12-24 | 贺新义 | Preparation method of green mulberry and citrus Pu' er tea |
Non-Patent Citations (2)
| Title |
|---|
| 孙素明: "三消愈康汤治疗非胰岛素依赖型糖尿病112例" * |
| 王民等: "常用降糖中药的药理分析" * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114848748B (en) | 2023-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104435775B (en) | A kind of Traditional Chinese medicinal health-care wine and preparation method thereof | |
| CN100353983C (en) | Chinese medicine preparation for reducing sugar | |
| CN106177053A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Pericarpium Citri Reticulatae | |
| CN110613134B (en) | Health food with blood sugar reducing function and preparation method thereof | |
| CN106177183A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, green tea and Folium Mori | |
| CN100493578C (en) | Chinese medicine composition for treating thin body and delicate constitution, and preparing method | |
| CN105582274A (en) | Pharmaceutical composition for treating female climacteric syndrome and preparing method thereof | |
| CN106177054A (en) | A kind of Hyperglycemic health care compositions comprising Cortex Mori and Pericarpium Citri Reticulatae | |
| CN114848748B (en) | Composition with blood sugar reducing effect and preparation method thereof | |
| CN100500174C (en) | Medicine composition used for lowering blood-sugar, preparation method and use thereof | |
| CN112336802A (en) | Traditional Chinese medicine composition for improving glycolipidosis metabolism of diabetes and application thereof | |
| CN105343675A (en) | Traditional Chinese medicine preparation for treating adiposis and preparation method thereof | |
| CN106581299B (en) | Traditional Chinese medicine composition for improving kidney qi deficiency of middle-aged and old people and application thereof | |
| CN106177476A (en) | A kind of Hyperglycemic health care compositions comprising Herba Dendrobii and Pericarpium Citri Reticulatae | |
| CN111939223A (en) | Traditional Chinese medicine composition with auxiliary blood sugar reduction effect and preparation method thereof | |
| CN103520684A (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN103393938A (en) | Traditional Chinese medicine composition for reducing blood sugar | |
| CN114588228B (en) | Composition for treating type 2 diabetes | |
| CN116236551B (en) | Traditional Chinese medicine composition for treating spleen deficiency and excessive dampness syndrome type spleen stomach diseases and preparation method thereof | |
| CN114869930B (en) | Silver bar powder for traditional Chinese medicine composition and preparation process and application thereof | |
| CN116440224B (en) | Traditional Chinese medicine composition, preparation and preparation method | |
| CN106376928A (en) | Method for preparing compound dendrobium officinale health product assisting in reducing blood sugar | |
| CN105560551A (en) | Traditional Chinese medicine composition for treating hyperlipidemia diseases and preparation method thereof | |
| CN106344808A (en) | Compound dendrobium officinale health care product capable of assisting in reducing blood sugar | |
| CN106173606A (en) | A kind of Hyperglycemic health care compositions comprising Cortex Mori and Herba Dendrobii |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A composition with hypoglycemic effect and its preparation method Granted publication date: 20230428 Pledgee: Pudong Development Bank of Shanghai Limited by Share Ltd. Shijiazhuang branch Pledgor: HEBEI YUZHILIN BIOTECHNOLOGY Co.,Ltd. Registration number: Y2024980013359 |